References
- McKeag D, Lane C, Lazarus JH, Baldeschi L, Boboridis K, Dickinson AJ, et al. Clinical features of dysthyroid optic neuropathy: a European Group on Graves’ Orbitopathy (EUGOGO) survey. Br J Ophthalmol 2007;91:455–458
- Choi YJ, Lim HT, Lee SJ, Lee SY, Yoon JS. Assessing Graves’ ophthalmopathy-specific quality of life in Korean patients. Eye 2012;26:544–551
- Wiersinga WM, Prummel MF, Mourits MP, Koornneef L, Buller HR. Classification of the eye changes of Graves’ disease. Thyroid 1991;1:357–360
- Terwee CB, Gerding MN, Dekker FW, Prummel MF, Wiersinga WM. Development of a disease specific quality of life questionnaire for patients with Graves’ ophthalmopathy: the GO-QOL. Br J Ophthalmol 1998;82:773–779
- Deramo VA, Cox TA, Syed AB, Lee PP, Fekrat S. Vision-related quality of life in people with central retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 2003;121:1297–1302
- Chakravarthy U, Stevenson M. Self-reported visual functioning and quality of life in age-related macular degeneration. Curr Opin Ophthalmol 2005;16:179–183
- Cole SR, Beck RW, Moke PS, Gal RL, Long DT. The National Eye Institute Visual Function Questionnaire: experience of the ONTT. Optic Neuritis Treatment Trial. Invest Ophthalmol Vis Sci 2000;41:1017–1021
- Wren PA, Musch DC, Janz NK, Niziol LM, Guire KE, Gillespie BW, et al. Contrasting the use of 2 vision-specific quality of life questionnaires in subjects with open-angle glaucoma. J Glaucoma 2009;18:403–411
- Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD, et al. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 2001;119:1050–1058
- Chan CW, Wong D, Lam CL, McGhee S, Lai WW. Development of a Chinese version of the National Eye Institute Visual Function Questionnaire (CHI-VFQ-25) as a tool to study patients with eye diseases in Hong Kong. Br J Ophthalmol 2009;93:1431–1436
- Bradley EA, Sloan JA, Novotny PJ, Garrity JA, Woog JJ, West SK. Evaluation of the National Eye Institute visual function questionnaire in Graves’ ophthalmopathy. Ophthalmology 2006;113:1450–1454
- Bartley GB, Gorman CA. Diagnostic criteria for Graves’ ophthalmopathy. Am J Ophthalmol 1995;119:792–795
- Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, et al. Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 2008;158:273–285
- Sidoti PA, Dunphy TR, Baerveldt G, LaBree L, Minckler DS, Lee PP, et al. Experience with the Baerveldt glaucoma implant in treating neovascular glaucoma. Ophthalmology 1995;102:1107–1118
- Estcourt S, Vaidya B, Quinn A, Shepherd M. The impact of thyroid eye disease upon patients’ wellbeing: a qualitative analysis. Clin Endocrinol (Oxf) 2008;68:635–639
- Charmaz K. The body, identity, and self. Sociol Q 1995;36:657–680
- Eye Disease Case-Control Study Group. Risk factors for central retinal vein occlusion. Arch Ophthalmol 1996;114:545–554
- Papageorgiou E, Hardiess G, Schaeffel F, Wiethoelter H, Karnath HO, Mallot H, et al. Assessment of vision-related quality of life in patients with homonymous visual field defects. Graefes Arch Clin Exp Ophthalmol 2007;245:1749–1758
- Yeatts RP. Quality of life in patients with Graves ophthalmopathy. Trans Am Ophthalmol Soc 2005;103:368–411